Design Therapeutics, Inc. (DSGN) Tops Q4 EPS by 10c

Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q4 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c